R&D Insights: How Summit Therapeutics Inc. and Amphastar Pharmaceuticals, Inc. Allocate Funds

Decade-long R&D spending trends in pharmaceuticals

__timestampAmphastar Pharmaceuticals, Inc.Summit Therapeutics Inc.
Wednesday, January 1, 20142842700015635076
Thursday, January 1, 20153706500023943601
Friday, January 1, 20164119900023689111
Sunday, January 1, 20174341500041006114
Monday, January 1, 20185756400051379106
Tuesday, January 1, 20196885300032705593
Wednesday, January 1, 20206722900053274000
Friday, January 1, 20216093200085352000
Saturday, January 1, 20227477100051999000
Sunday, January 1, 20237374100059471000
Loading chart...

Infusing magic into the data realm

R&D Spending Trends: A Decade of Innovation

In the ever-evolving pharmaceutical landscape, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Amphastar Pharmaceuticals, Inc. and Summit Therapeutics Inc. have demonstrated distinct strategies in their R&D allocations.

From 2014 to 2023, Amphastar Pharmaceuticals consistently increased its R&D expenses, peaking in 2022 with a 163% rise from its 2014 levels. This upward trend underscores Amphastar's dedication to expanding its research capabilities. Meanwhile, Summit Therapeutics showcased a more volatile pattern, with a notable surge in 2021, where R&D spending jumped by 445% compared to 2014. This spike highlights Summit's strategic pivot towards intensive research initiatives.

These trends reflect broader industry dynamics, where strategic R&D investments are pivotal for maintaining competitive advantage and driving future growth.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025